#HPB Surgeon in @hgermanstrias. @UABBarcelona Professor of Surgery. @BerkeleyHaas Entrepreneur. @RUTILIGHT medical advisor. @ILLS_LAPLIVER founding member.
How common is recurrent cholangitis after Whipple/HJ without HJ-stenosis (NSC)? And how to treat? Today in @hpbjournal
🔑 50 of 1179 (4.2%) pts with HJ developed non-stenotic cholangitis NSC.
🔑 'step-up approach' with short-course antibiotics (n = 50, 100 %), prolonged antibiotics (n = 26, 52%), and revisional surgery (n = 7, 14 %).
🔑 Resolution of NSC in 15 pts (30%) and reduction of NSC frequency in an additional 21 pts (42%).
🔑 Concomitant UDCA use and stopping PPI = only predictor for resolution (OR 4.229, p = 0.035).
🔑 Secondary sclerosing cholangitis occurred in 12 pts (24%), associated with the nr of NSC episodes (OR 1.2, p = 0.050).
▶️ https://t.co/qQx0DVJK9g
Great meeting Spanish Society Surgeons 🇪🇸 #Madrid#CNC2024: Speaking on #evidence for Robot 🤖 Whipple
🔑 high volume center required (>50 Whipples/year) for pt benefit
🔑 LEARNBOT @EAHPBA@e_mips training program available in Europe
🔑 Outcomes via @e_mips #registry
🔑 3 RCTs now available
🙏thank CNC for the Honorary Membership
For the first time worldwide we use Apple vision pro with the Da Vinci Xi robotic platform @IntuitiveSurg . Thanks to the collaboration of @hgermanstrias and @mSurgeryNet the first assistant can have the same immersive 3D view as the console surgeon.@BalibreaJose@DrPau
Liver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohort
➡️ https://t.co/rjOG18NqOH
The #multicentre international retrospective DRAGON 0 study showed that simultaneous portal (PVE) and hepatic vein (HVE) embolization in patients with cancer in the liver increases the future liver remnant hypertrophy, kinetic growth rate, and resection rate compared with PVE alone.
Mid-term oncological follow-up showed that median 3-year overall survival was significantly increased in the PVE/HVE group.
Great work by Remon Korenblik, Jan Heil, Jens Smits, Sinead James, Bram Olij, Wolf O Bechstein, Marc H A Bemelmans, Christoph A Binkert, Stefan Breitenstein, Michael Williams, Olivier Detry, Maxime J L Dewulf, Alexandra Dili, Lukasz F Grochola, Jon Grote, Daniel Heise, Jennifer A Kalil, Peter Metrakos, Ulf P Neumann, Sam G Pappas, Francesca Pennetta, Andreas A Schnitzbauer, Jordan C Tasse, Bjorn Winkens, Steven W M Olde Damink, Christiaan van der Leij, Erik Schadde, Ronald M van Dam, DRAGON trials collaborative
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos@SEIQuirurgica@iss_sic #MedicalTechniques @BJSAcademy@young_bjs@BJSOpen@des_winter@evanscolorectal@robhinchliffe1@bplwijn@ksoreide@MalinASund@nfmkok@TejedorPat@paulo_sutt@PVaughanShaw@JJEarnshaw@juliomayol #some4hpb #some4tpl
Honored to have with us so vip colleagues. Advanced laparoscopic liver resection, hemihepatectomy with intraglissonean approach @hpb_so@oliviawriting Hope to see you very soon!
RCT Laparoscopic vs Open Hemihepatectomy? #liver#surgery#ORANGE2plus published @JCO_ASCO: ➡️332 pts; 166 lap vs 166 open in 16 European centers 🇳🇱🇬🇧🇧🇪🇮🇹🇳🇴.
🔑 time to recovery 4 vs 5 days, p<.001
🔑 major complic. 14.5 vs 16.9%, p=.58
🔑 global health status, p<.001
🔑 body image, p<.001
🔑 R0 resection 77.9% vs 84.1%, p=.14🔑 time to adj th 47 vs 63 dys, p=.009
Great Team effort Ronald van Dam, John Primrose, @Abuhilal9Abu & friends
https://t.co/nFBulmvxoh
🤔Decidint la plaça per fer la residència #MIR2024#IIR2024?
🤗Vine a les Jornades de Portes Obertes i informa't sobre la residència a #hgermanstrias
👤 Acte Presencial
🗓️ 20 de març
🕘 de 9 a 12h
📍 Sala d'actes
✏️Inscripció https://t.co/hs44lY1ivJ
🎯 #TriaGermansTrias
Is it safe to stop placing a drain after distal pancreatectomy?
➡️Today #PANDORINA non-inferiority trial 🇳🇱🇮🇹 @LancetGastroHep
✅ Yes! Not only safe, but improves overall morbidity and POPF B/C rate!
Wonderful collaboration @DPCG_official & @PancreasVerona
➡️ https://t.co/gJKen6PgOp